Adaptive Biotechnologies Quote - ADPT

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

5.995

Bid

5.60

Ask

6.48

Volume

0.00 Day's Range 0.00

2.28 52 Week Range 7.0665

Market Cap

884.739M

Previous Close

5.995

Open

Last Trade

5.86

Last Trade Time

03:44:21

Financial Volume

VWAP

Average Volume (3m)

1,191,589

Shares Outstanding

147,579,486

Dividend Yield

PE Ratio

-3.92

Earnings Per Share (EPS)

-1.53

Revenue

170.28M

Net Profit

-225.25M

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for... Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.adaptivebiotech.com

Headquarters

Olympia, Washington, USA

Founded

Adaptive Biotechnologies Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ADPT. The last closing price for Adaptive Biotechnologies was US$6. Over the last year, Adaptive Biotechnologies shares have traded in a share price range of US$ 2.28 to US$ 7.0665.

Adaptive Biotechnologies currently has 147,579,486 shares outstanding. The market capitalization of Adaptive Biotechnologies is US$884.74 million. Adaptive Biotechnologies has a price to earnings ratio (PE ratio) of -3.92.

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment...

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.345	-5.44164037855	6.34	6.52	5.86	735079	6.20542531	CS
4	-0.315	-4.99207606973	6.31	7.0665	5.805	1043281	6.32473706	CS
12	1.125	23.1006160164	4.87	7.0665	4.27	1191589	5.5314502	CS
26	2.395	66.5277777778	3.6	7.0665	3.3	1201126	4.95551502	CS
52	1.055	21.3562753036	4.94	7.0665	2.28	1380180	4.11555907	CS
156	-22.125	-78.6806543385	28.12	28.92	2.28	1295612	6.92134239	CS
260	-24.005	-80.0166666667	30	71.25	2.28	1143835	17.38038832	CS

ADPT - Frequently Asked Questions (FAQ)

What is the current Adaptive Biotechnologies share price?

The current share price of Adaptive Biotechnologies is US$ 5.995

How many Adaptive Biotechnologies shares are in issue?

Adaptive Biotechnologies has 147,579,486 shares in issue

What is the market cap of Adaptive Biotechnologies?

The market capitalisation of Adaptive Biotechnologies is USD 884.74M

What is the 1 year trading range for Adaptive Biotechnologies share price?

Adaptive Biotechnologies has traded in the range of US$ 2.28 to US$ 7.0665 during the past year

What is the PE ratio of Adaptive Biotechnologies?

The price to earnings ratio of Adaptive Biotechnologies is -3.92

What is the cash to sales ratio of Adaptive Biotechnologies?

The cash to sales ratio of Adaptive Biotechnologies is 5.19

What is the reporting currency for Adaptive Biotechnologies?

Adaptive Biotechnologies reports financial results in USD

What is the latest annual turnover for Adaptive Biotechnologies?

The latest annual turnover of Adaptive Biotechnologies is USD 170.28M

What is the latest annual profit for Adaptive Biotechnologies?

The latest annual profit of Adaptive Biotechnologies is USD -225.25M

What is the registered address of Adaptive Biotechnologies?

The registered address for Adaptive Biotechnologies is 711 CAPITOL WAY S STE 204, UNITED STATES, OLYMPIA, WASHINGTON, 98501 1267

What is the Adaptive Biotechnologies website address?

The website address for Adaptive Biotechnologies is www.adaptivebiotech.com

Which industry sector does Adaptive Biotechnologies operate in?

Adaptive Biotechnologies operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
RAINRain Enhancement Technologies Holdco Inc	11.39 (841.32%)	250
REVBRevelation Biosciences Inc	US$ 1.10 (138.61%)	24.76M
TOIIWOncology Institute Inc	US$ 0.0123 (136.54%)	4.47k
CGBSCrown LNG Holdings Ltd	US$ 0.8696 (117.35%)	33.31M
AEIAlset Inc	US$ 2.20 (115.69%)	15.08M
SIDUSidus Space Inc	US$ 3.18 (-35.10%)	1.53M
BDMDBaird Medical Investment Holdings Ltd	US$ 5.05 (-33.55%)	319.43k
AIPArteris Inc	US$ 8.01 (-21.39%)	49
BFINBankFinancial Corporation	US$ 10.01 (-21.15%)	9
LNSRLENSAR Inc	US$ 7.15 (-20.02%)	1
CMCTCreative Media and Community Trust Corporation	US$ 0.2764 (22.84%)	42.28M
CGBSCrown LNG Holdings Ltd	US$ 0.8808 (120.14%)	33.35M
SVMHSRIVARU Holding Ltd	US$ 0.0468 (11.16%)	32.36M
REVBRevelation Biosciences Inc	US$ 1.12 (142.95%)	24.76M
ALCEAlternus Clean Energy Inc	US$ 1.64 (108.70%)	19.95M